Abstract
INTRODUCTION
Growing evidence suggests a role for neuroinflammation in Alzheimer’s disease (AD). We investigated complement pathway activity in AD patient cerebrospinal fluid (CSF) and evaluated its modulation by the anti-tau antibody semorinemab.
METHODS
Immunoassays were applied to measure CSF complement proteins C4, factor B (FB), C3 and their cleavage fragments C4a, C3a, and factor Bb (Bb) in AD patients and a separate cognitively unimpaired (CU) cohort.
RESULTS
All measured CSF complement proteins were increased in AD versus CU subjects, with C4a displaying the most robust increase. Finally, semorinemab did not have a significant pharmacodynamic effect on CSF complement proteins.
DISCUSSION
Elevated levels of CSF C4a, C4, C3a, C3, Bb, and FB are consistent with complement activation in AD brains. Despite showing a reduction in CSF soluble tau species, semorinemab did not impact complement protein levels or activity. Further studies are needed to determine the value of complement proteins as neuroinflammation biomarkers in AD.
Highlights
Cerebrospinal fluid (CSF) complement proteins C4a, C3a, Bb, C4, C3, and factor B levels were increased in Alzheimer’s disease (AD) patients compared to a separate cognitively unimpaired (CU) cohort.
Baseline CSF complement protein levels were correlated with neuro-axonal degeneration and glial activation biomarkers in AD patients.
The investigational anti-tau antibody semorinemab did not impact CSF complement protein levels or activity relative to the placebo arm.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Cosme Sandoval,
Julie Lee,
Balazs Toth,
Rajini Nagaraj,
Stephen P. Schauer,
Jennifer Hoffman,
Emilia Calderon,
Gwendlyn Kollmorgen,
Sandra M. Sanabria Bohórquez,
Cecilia Monteiro,
Edmond Teng,
Jesse E. Hanson,
Felix L. Yeh,
Johnny Gutierrez,
Anne Biever | October 6, 2024